Certara, Inc. (CERT) experienced a sharp decline of 5.04% in its stock price on November 7, 2024, as the company grappled with challenges in its regulatory services segment and analysts revised their ratings and price targets.
The drop in Certara's stock followed the company's Q3 2024 earnings call, during which it reported strong revenue growth of 11% year-over-year, driven by robust performance in its biosimulation software and services. However, the regulatory services market proved more challenging than expected, leading to a modest revision in Certara's 2024 guidance.
Analysts from JMP Securities and Barclays maintained their "Hold" ratings on CERT stock, with Barclays lowering its price target from $14 to $12, potentially impacting investor sentiment. The company acknowledged a divergence in growth profiles between its regulatory services and core biosimulation businesses, with the latter showing stronger performance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。